How much funding has Reneo Pharmaceuticals raised?

Reneo Pharmaceuticals has raised $145.0M in total funding, most recently a series b round.

Who are Reneo Pharmaceuticals's investors?

Reneo Pharmaceuticals's investors include Novo Holdings, Abingworth, New Enterprise Associates, Jefferies, SVB Leerink, Piper Sandler.

When was Reneo Pharmaceuticals founded?

Reneo Pharmaceuticals was founded in 2014.

Where is Reneo Pharmaceuticals headquartered?

Reneo Pharmaceuticals is headquartered in San Diego, California, United States.

What industry is Reneo Pharmaceuticals in?

Reneo Pharmaceuticals operates in Biotech, Rare Diseases.

How many employees does Reneo Pharmaceuticals have?

Reneo Pharmaceuticals has 11-50 employees.

Reneo Pharmaceuticals

IPO

Xoilac TV | Trực Tiếp Bóng Đá HD - Link Xôi Lạc TV #1 Hôm Nay

Public · San Diego, United States · Founded 2014 · $145.0M raised

Biotech

Rare Diseases

Headquarters: San Diego, California
Employees: 11–50
Founded: 2014
Business Model: B2B
Website: reneopharma.com

Total Funding: $145.0M
Last Round: $95.0M Series BDec 2020
Rounds: 2
Type: Public

About

Reneo Pharmaceuticals was a clinical-stage biopharmaceutical company founded in 2014 in San Diego, California, focused on the development of therapies for patients with rare genetic mitochondrial diseases. Reneo's lead program, REN001 (a PPARdelta agonist), targeted primary mitochondrial myopathy. The company went public on Nasdaq in April 2021 under the symbol RPHM. Following a Phase 2b clinical trial failure in May 2024, Reneo merged with OnKure Therapeutics, closing the merger in October 2024.

Summary

Reneo Pharmaceuticals is a Biotech company based in San Diego, United States, founded in 2014. It has raised $145.0M in total across 2 rounds, most recently a $95.0M Series B round in Dec 2020. Investors include Novo Holdings, Abingworth and New Enterprise Associates.